DMA.V : Summary for DIAMEDICA THERAPEUTICS INC - Yahoo Finance

U.S. Markets closed

DiaMedica Therapeutics Inc. (DMA.V)

TSXV - TSXV Delayed Price. Currency in CAD
Add to watchlist
0.180.00 (0.00%)
At close: 1:57PM EST
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close0.18
Bid0.19 x
Ask0.19 x
Day's Range0.17 - 0.18
52 Week Range0.14 - 0.35
Avg. Volume112,303
Market Cap19.89M
PE Ratio (TTM)-5.29
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Zacks Small Cap Research4 days ago

    DMA.V: DM199 and Diabetic Kidney Disease (DKD)

    In addition to AIS, DiaMedica (DMA.V) (DMCAF) is also developing DM199 for the treatment of diabetic kidney disease (DKD). Diabetic kidney disease (DKD) or Diabetic nephropathy (DN) is one of the most common complications of late stage diabetes. DKD is a form of chronic kidney disease (CKD) characterized by a gradual loss of kidney function.

  • Zacks Small Cap Research4 days ago

    DiaMedica: A Key Player in the area of AIS and DKD

    DiaMedica Therapeutics Inc. (DMA.V) (DMCAF) is a clinical stage biopharmaceutical company focused on the development and commercialization of DM199 for the treatment of acute ischemic stroke (AIS) and diabetic kidney disease (DKD). The company’s lead drug candidate DM199 is a recombinant human tissue kallikrein (KLK1). DM199 has undergone clinical testing that demonstrates its exceptional safety as a potential treatment for a variety of disorders.

  • Marketwired2 months ago

    DiaMedica Announces Name Change to DiaMedica Therapeutics Inc.

    DiaMedica Inc. announced today it will change its name to DiaMedica Therapeutics Inc.